REPLIGEN CORP Finite-Lived Intangible Asset, Expected Amortization, Year One
REPLIGEN CORP (RGEN) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $38.36 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-07-29
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $38.36M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $38.45M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $39.40M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $39.39M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One | Finite-Lived Intangible Asset, Expected Amortization, Year One as first filed |
|---|---|---|
| 2026-06-30 | $38.36M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $38.45M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $39.40M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $39.39M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $39.51M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $37.55M 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $36.02M 10-K · filed 2025-03-14 | |
| 2024-09-30 | $34.35M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $17.12M 10-Q/A · filed 2024-11-18 | $16.88M 10-Q · filed 2024-07-30 |
| 2024-03-31 | $25.80M 10-Q/A · filed 2024-11-18 | $25.45M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $34.78M 10-K/A · filed 2024-11-18 | $34.31M 10-K · filed 2024-02-22 |
| 2023-09-30 | $7.62M 10-Q/A · filed 2024-11-18 | $7.50M 10-Q · filed 2023-10-31 |
| 2023-06-30 | $15.27M 10-Q/A · filed 2024-11-18 | $15.03M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $22.43M 10-Q/A · filed 2024-11-18 | $22.07M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $29.29M 10-K · filed 2023-02-22 | |
| 2022-09-30 | $29.14M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $26.25M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $26.35M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $26.50M 10-K · filed 2022-02-17 | |
| 2021-09-30 | $25.84M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $20.75M 10-Q · filed 2021-07-27 | |
| 2021-03-31 | $20.74M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $20.77M 10-K · filed 2021-02-24 | |
| 2018-12-31 | $10.54M 10-K · filed 2019-03-01 | |
| 2017-12-31 | $10.63M 10-K · filed 2018-02-22 | |
| 2016-12-31 | $2.85M 10-K · filed 2017-02-23 | |
| 2015-12-31 | $1.70M 10-K · filed 2016-02-25 | |
| 2014-12-31 | $1.70M 10-K · filed 2015-03-17 | |
| 2013-12-31 | $1.00M 10-K · filed 2014-03-14 | |
| 2012-12-31 | $1.00M 10-K · filed 2013-03-15 | |
| 2012-09-30 | $978.00K 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $978.00K 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |